gimli
BAJAJHCARE stock AI analysis

BAJAJHCARE Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

BAJAJ HEALTHCARE LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available BAJAJHCARE price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Price
₹330.55
1W return
-0.83%
1M return
+2.58%
3M return
+4.24%
6M return
+7.30%
1Y return
-22.55%
Market cap
₹1,112.72 cr
PE
63.12
PB
2.09
ROE
+3.53%
ROCE
+4.41%
RSI
51.98
Turnover
₹1.39 cr

Why it can matter in screens

Quick Answers

What is the latest BAJAJHCARE stock price?

The latest stored price for BAJAJHCARE is Rs 330.55 as of 2026-09-18.

Is BAJAJHCARE above its 50DMA and 200DMA?

BAJAJHCARE is below 50DMA, below 200DMA. The latest 50DMA is 332.91 and the latest 200DMA is 342.28.

What are BAJAJHCARE PE, ROE and ROCE?

BAJAJHCARE has PE 63.12, ROE +3.53%, and ROCE +4.41% in Gimli's latest available snapshot.

How has BAJAJHCARE performed recently?

BAJAJHCARE has returned +2.58% over 1 month, +4.24% over 3 months, and -22.55% over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

PeriodRevenueEBITDAPATEPS
2026-06-30165.63 cr29.56 cr13.70 cr4.07
2026-03-31153.06 cr-7.61 cr-22.85 cr-7.16
2025-12-31161.22 cr32.33 cr15.67 cr4.96
2025-09-30149.56 cr28.60 cr11.11 cr3.47
2025-06-30148.84 cr25.39 cr11.83 cr3.74
2025-03-31154.47 cr25.33 cr11.18 cr3.54
2024-12-31122.79 cr24.01 cr11.72 cr3.65
2024-09-30133.09 cr27.13 cr9.46 cr3.36

Annual income statement

YearRevenueEBITDAPATEPS
2026-03-31611.03 cr78.71 cr15.77 cr4.98
2025-03-31542.60 cr101.83 cr39.50 cr13.29
2024-03-31472.93 cr43.83 cr-83.79 cr-30.36
2023-03-31645.80 cr121.94 cr43.02 cr15.59
2022-03-31681.33 cr118.32 cr71.39 crnan

Balance sheet

PeriodAssetsCashDebtEquity
2026-03-31923.22 cr37.24 cr249.09 cr533.00 cr
2025-03-31833.05 cr2.60 cr223.25 cr466.16 cr
2024-03-31765.13 cr2.17 cr332.82 cr278.36 cr
2023-03-31897.66 cr17.72 cr415.24 cr367.69 cr
2022-03-31721.10 cr1.98 cr256.74 cr328.49 cr

Cash flow

PeriodOCFFCFCash change
2026-03-3158.08 cr14.73 crn/a
2025-03-3121.62 cr10.08 crn/a
2024-03-3192.29 cr62.01 crn/a
2023-03-31-22.19 cr-115.79 crn/a
2022-03-310.69 cr-78.62 crn/a

Shareholding Trend

PeriodPromoterFII/FPIDIIMFRetailPledge
2026-06-30+58.59%+2.19%+1.92%+1.69%+37.30%+0.00%
2026-03-31+58.29%+1.98%+2.91%+1.69%+36.82%+0.00%
2026-03-18+58.29%+1.53%+2.91%+1.69%+37.27%+0.00%
2025-12-31+59.19%+1.18%+2.96%+1.66%+36.67%+0.00%
2025-09-30+59.19%+1.12%+3.00%+1.66%+36.70%+0.00%
2025-06-30+59.19%+1.09%+3.16%+1.66%+36.56%+0.00%
2025-03-31+59.19%+1.05%+2.52%+1.64%+37.24%+0.00%
2024-12-31+59.19%+1.01%+2.36%+1.64%+37.45%+0.00%
2024-09-30+59.19%+1.07%+1.97%+1.31%+37.78%+0.00%
2024-09-19+59.19%+2.46%+1.97%+1.31%+36.39%+0.00%
2024-06-30+67.73%+0.01%+0.00%+0.00%+32.26%+0.00%
2024-03-31+67.73%+0.53%+0.44%+0.00%+31.30%+0.00%
2023-12-31+67.73%+0.74%+0.48%+0.00%+31.06%n/a
2023-09-30+67.69%+0.66%+0.44%+0.00%+31.22%+0.00%
2023-06-30+67.49%+0.69%+0.34%+0.00%+31.48%+0.00%
2023-03-31+67.49%+0.78%+0.34%+0.00%+31.39%+0.00%
2022-12-31+67.42%+0.94%+0.34%+0.00%+31.30%+0.00%
2022-09-30+67.30%+0.09%+0.00%+0.00%+32.61%+0.00%
2022-06-30+67.30%+0.00%+0.32%n/an/a+0.00%
2022-03-31+67.26%+0.00%+0.38%n/an/a+0.00%

Industry Peers

SymbolNameMcapPEROE1Y
SUNPHARMASUN PHARMACEUTICAL IND L440,829.82 cr36.388220+15.50%+11.45%
DIVISLABDIVI S LABORATORIES LTD248,876.81 cr85.407280+18.37%+53.39%
TORNTPHARMTORRENT PHARMACEUTICALS L163,807.57 cr75.106636+17.33%+35.67%
APOLLOHOSPAPOLLO HOSPITALS ENTER. L128,608.22 cr65.670049+21.03%+13.94%
ZYDUSLIFEZYDUS LIFESCIENCES LTD116,723.14 cr26.011308+16.04%+10.70%
CIPLACIPLA LTD112,647.78 cr33.401961+10.25%-11.64%
LAURUSLABSLAURUS LABS LIMITED105,487.98 cr96.587446+21.77%+111.64%
MAXHEALTHMAX HEALTHCARE INS LTD102,122.47 cr70.799892+14.33%-10.58%

Try these prompts

Related screen ideas

Data snapshot: 2026-09-18. Not investment advice.